These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 15740555

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M, Yonan N, Ross H, Miller LW, Sechaud R, Balez S, Koelle EU, Gerosa G, ERL 2401 Study Group.
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.
    Transplantation; 2007 Feb 27; 83(4):417-24. PubMed ID: 17318074
    [Abstract] [Full Text] [Related]

  • 7. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
    Tedesco-Silva H, Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Slade A, Schmouder R, Medina-Pestana JO.
    Clin Transplant; 2010 Feb 27; 24(4):E116-23. PubMed ID: 20047618
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
    Graff J, Scheuermann EH, Brandhorst G, Oellerich M, Gossmann J.
    Ther Drug Monit; 2016 Jun 27; 38(3):388-92. PubMed ID: 26829599
    [Abstract] [Full Text] [Related]

  • 9. Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.
    Arns W, Gies M, Choi L, Zhu W, Cooper P, Yeh CM, Prasad P, Graf P, Schmouder R.
    Int J Clin Pharmacol Ther; 2006 Aug 27; 44(8):375-85. PubMed ID: 16961168
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
    Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D.
    Expert Opin Pharmacother; 2010 Apr 27; 11(5):689-99. PubMed ID: 20210680
    [Abstract] [Full Text] [Related]

  • 11. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
    Capone D, Tarantino G, Kadilli I, Polichetti G, Basile V, Federico S, Sabbatini M.
    Nephrol Dial Transplant; 2011 Sep 27; 26(9):3019-25. PubMed ID: 21317409
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.
    Transplant Rev (Orlando); 2011 Apr 27; 25(2):47-57. PubMed ID: 21190834
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
    Belliere J, Esposito L, Gandia P, Duffas JP, Sallusto F, Cardeau-Desangles I, Del Bello A, Rostaing L, Kamar N.
    Ann Transplant; 2014 Feb 10; 19():76-81. PubMed ID: 24509827
    [Abstract] [Full Text] [Related]

  • 18. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G, MYVIDA Study Group.
    Transplantation; 2011 Aug 27; 92(4):426-32. PubMed ID: 21760569
    [Abstract] [Full Text] [Related]

  • 19. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

  • 20. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.
    Transplant Proc; 2007 Sep 27; 39(7):2194-6. PubMed ID: 17889135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.